News
As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...
The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...
A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...
The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...
Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...
Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback